Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118).
/in Dendritic Cells, Urothelial Carcinoma /von 2019-06-01 / J Clin Oncol 37, 2019 (suppl; abstr 2639)Neoantigen-based personalized DC vaccine for lung cancer: An update of translational study.
/in Dendritic Cells, NSCLC /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e20674)Dynamics of the immune status in patients with cervical cancer receiving complex treatment with dendritic cell vaccine.
/in Cervical Cancer, Dendritic Cells /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e17005)Combination therapy of dendritic cell vaccination plus chemotherapy in pancreatic cancer.
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e15748)Dendritic cell vaccination in metastatic uveal melanoma as compassionate treatment: Immunological and clinical responses.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e21024)Patient-specific dendritic cell vaccines with autologous tumor antigens in 72 patients with metastatic melanoma
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-05-31 / Melanoma Manag 2019 May;6(2):MMT20Clinical efficacy of vaccination with the autologous tumor lysate particle loaded dendritic cell (TLPLDC) vaccine in metastatic melanoma.
/in Dendritic Cells, International Publications, Malignant Melanoma /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e21025)Effect of targeting CD40 for DC vaccination in pancreatic adenocarcinoma.
/in Dendritic Cells, International Publications, Pancreatic Cancer /von 2019-05-31 / J Clin Oncol 37, 2019 (suppl; abstr e15783)Adjuvant dendritic cell based immunotherapy (DCBI) after cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC) for peritoneal mesothelioma, a phase II single centre open-label clinical trial: rationale and design of the MESOPEC trial
/in Dendritic Cells, International Publications, Malignant Pleural Mesothelioma /von 2019-05-14 / BMJ Open 2019 05;9(5):e026779
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de